期刊文献+

人乳头瘤病毒16L1/E7CTL重组杆状病毒载体的构建及鉴定

Construction and Identification of the Recombinant Bacmid of Human Papillomavirus 16 L1/E7CTL Gene
下载PDF
导出
摘要 目的研制人乳头瘤病毒16型(HPV16)L1/E7CTL重组杆状病毒载体。方法以包含HPV16标准病毒株的质粒pHPV16为模板,采用PCR技术扩增HPV16主要衣壳蛋白L1(1-471aa)的基因序列,同时人工合成E7蛋白CTL表位E749-57的编码序列,将两个目的基因逐步连接构建重组质粒pUC19HPV16L1/E7CTL,HPV16L1/E7CTL片段经质粒pFast Bac1转位至Bacmid DNA后通过PCR鉴定重组杆粒。结果成功构建了包含融合基因HPV16L1/E7CTL片段的克隆质粒pUC19HPV16L1/E7CTL,制备了L1/E7CTL重组杆状病毒载体杆粒BACMID DNA。结论采用分子克隆技术构建了包含L1/E7CTL的重组杆粒BACMID DNA,有利于下一步融合蛋白的表达,制备一种能够更有效激发CTL杀伤作用的嵌合病毒样颗粒疫苗,为疫苗研制打下基础。 Objective To construct and identify a recombinant Baculovirus Bacmid DNA vector of Human Papillomavirus16(HPV16) L1/E7CTL. Methods Amplified major capsid protein L1 (1-471aa) gene sequence by Polyenzyme Chain Reaction (PCR), taking standard virus pHPV 16 as a plate. The composed E749-57 coding gene was combined to L1 to construct recombinant plasmid pUC19HPV16L1/E7CTL HPV16L1/E7CTL sequence was transferred to Bacmid DNA by deliver plasmid pFast Bacl, and the recombinant Bacmid DNA was identified by PCR. Results Plasmid pUC19HPV16L1/ E7CTL including the combined genes and recombinant Bacmid DNA were constructed. Conclusion These data indicate that recombinant Bacmid DNA vector of HPV16L1/ETCTL was constructed. It is helpful to express recombinant protein and prepare a more effective chimeric virus-liked vaccin next step, and it also can be a foundation for HPV vaccines technology exploration.
出处 《中国中西医结合皮肤性病学杂志》 CAS 2007年第1期7-10,共4页 Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine
基金 广东省科技计划攻关项目资助(2KM05301S)
关键词 乳头瘤病毒16型 重组杆状病毒 疫苗 papillomavirus 16, human recombinant baculovirus vector vaccine
  • 相关文献

参考文献2

  • 1徐云升,郝飞,宋志强,钟白玉,郝进,叶庆佾.HPV16E7抗原的HLA-A2限制性细胞毒性T淋巴细胞表位的筛选与鉴定[J].中华皮肤科杂志,2004,37(5):283-284. 被引量:6
  • 2Alfonso Ferrara,Marion Nonn,Peter Sehr,Carola Schreckenberger,Michael Pawlita,Matthias Dürst,Achim Schneider,Andreas M. Kaufmann. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients[J] 2003,Journal of Cancer Research and Clinical Oncology(9):521~530

二级参考文献7

  • 1Fujie T, Tahara K, Tanaka F, et al. A MAGE-1-encoded HLAA24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer, 1999, 80:169-172.
  • 2de Jong A, O'Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine, 2002, 20:3456-3464.
  • 3Oiso M, Eura M, Katsura F, et al. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer, 1999, 81:387-394.
  • 4Yewdell JW,Hill AB.Viral interference with antigen presentation.Nat Immunol,2002,3:1019-1025.
  • 5唐旭,赵玉铭,董小平,何春涤,王雅坤,陈洪铎.尖锐湿疣患者外周血中HPVDNA的检测[J].中华皮肤科杂志,2003,36(5):258-260. 被引量:13
  • 6徐云升,郝飞,钟白玉,郝进,叶庆佾,4郑江.人乳头瘤病毒16 E7抗原细胞毒性T细胞预测表位合成肽的纯化与鉴定[J].中华皮肤科杂志,2003,36(5):284-284. 被引量:3
  • 7徐云升,郝飞.HPV16型E7抗原表位的研究进展[J].中华皮肤科杂志,2003,36(5):300-302. 被引量:2

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部